Dysregulated homeobox genes are promising biomarkers for the diagnosis, prognosis, and therapy of bladder cancer, as they are directly associated with bladder tumorigenesis and clinically relevant bladder cancer outcomes. Here, LBX1 is linked to urogenital neoplasm.